Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Тактика ведения пациентов с разными формами гастроэзофагеальной рефлюксной болезни
Тактика ведения пациентов с разными формами гастроэзофагеальной рефлюксной болезни
Для цитирования: Трухманов А.С., Румянцева Д.Е. Тактика ведения пациентов с разными формами гастроэзофагеальной рефлюксной болезни. Гастроэнтерология. Хирургия. Интенсивная терапия. Consilium Medicum. 2019; 1: 7–12. DOI: 10.26442/26583739.2019.1.190242
DOI: 10.26442/26583739.2019.1.190242
________________________________________________
DOI: 10.26442/26583739.2019.1.190242
Материалы доступны только для специалистов сферы здравоохранения. Авторизуйтесь или зарегистрируйтесь.
Аннотация
Цель. Представить современные данные о методах диагностики и способах лечения различных форм гастроэзофагеальной рефлюксной болезни (ГЭРБ).
Основные положения. ГЭРБ занимает лидирующие позиции среди заболеваний желудочно-кишечного тракта. Ее распространенность в Российской Федерации составляет 18–46%. Пациентам с характерной клинической симптоматикой необходимо проведение эзофагогастродуоденоскопии с биопсией слизистой оболочки пищевода для верификации формы ГЭРБ и исключения очагов кишечной метаплазии и дисплазии. Также диагностические подходы включают в себя проведение 24-часовой рН-импедансометрии, манометрии пищевода высокого разрешения, которые позволят не только исключить функциональную изжогу, но и назначить индивидуализированную терапию с учетом характера рефлюктата и двигательных нарушений. Препаратами выбора для лечения всех форм ГЭРБ являются ингибиторы протонной помпы. При этом эзомепразол продемонстрировал свою эффективность при неэрозивной рефлюксной болезни, эрозивном рефлюкс-эзофагите, рефрактерном течении заболевания. Кроме того, эзомепразол применяется для поддерживающей терапии ГЭРБ. Хирургическое лечение больных, страдающих ГЭРБ, должно проводиться после тщательного обследования и по строгим показаниям.
Заключение. Результаты лечения и профилактики осложнений ГЭРБ определяются правильной своевременной диагностикой заболевания с учетом индивидуальных особенностей каждого пациента. Это позволяет выбрать оптимальную тактику лечения и улучшить качество оказания медицинской помощи.
Ключевые слова: гастроэзофагеальная рефлюксная болезнь, ингибиторы протонной помпы, эзомепразол, пищевод Барретта, неэрозивная рефлюксная болезнь.
Main points. Gastro-esophageal reflux disease occupies the leading position among the gastrointestinal tract disorders. Its prevalence in the Russian Federation is 18–46%. Patients with characteristic clinical symptoms require esophagogastroduodenoscopy with biopsy of the esophageal mucosa to verify the form of GERD and to exclude foci of intestinal metaplasia and dysplasia. In addition, diagnostic approaches include 24-hour pH-impedancemetry and esophagus manometry which allow you not only to exclude functional heartburn but also to prescribe an individualized therapy based on a nature of an refluxate and motor disorders. Proton pump inhibitors (PPI) are the drugs of choice for a treatment of all forms of GERD. Esomeprazole has demonstrated efficacy in a treatment of non-erosive reflux disease, erosive reflux esophagitis and refractory course of the disease. In addition, esomeprazole is used for maintenance therapy of GERD. Surgical treatment of patients with GERD should be carried out following a meticulous examination and according to strict indications.
Conclusion. The results of treatment and prevention of GERD complications are determined by a proper timely diagnosis of the disease, given individual characteristics of each patient. This allows you to choose the optimal treatment tactics and to improve a quality of medical care.
Key words: gastro-esophageal reflux disease, proton pump inhibitors, esomeprazole, Barrett’s esophagus, non-erosive reflux disease
Основные положения. ГЭРБ занимает лидирующие позиции среди заболеваний желудочно-кишечного тракта. Ее распространенность в Российской Федерации составляет 18–46%. Пациентам с характерной клинической симптоматикой необходимо проведение эзофагогастродуоденоскопии с биопсией слизистой оболочки пищевода для верификации формы ГЭРБ и исключения очагов кишечной метаплазии и дисплазии. Также диагностические подходы включают в себя проведение 24-часовой рН-импедансометрии, манометрии пищевода высокого разрешения, которые позволят не только исключить функциональную изжогу, но и назначить индивидуализированную терапию с учетом характера рефлюктата и двигательных нарушений. Препаратами выбора для лечения всех форм ГЭРБ являются ингибиторы протонной помпы. При этом эзомепразол продемонстрировал свою эффективность при неэрозивной рефлюксной болезни, эрозивном рефлюкс-эзофагите, рефрактерном течении заболевания. Кроме того, эзомепразол применяется для поддерживающей терапии ГЭРБ. Хирургическое лечение больных, страдающих ГЭРБ, должно проводиться после тщательного обследования и по строгим показаниям.
Заключение. Результаты лечения и профилактики осложнений ГЭРБ определяются правильной своевременной диагностикой заболевания с учетом индивидуальных особенностей каждого пациента. Это позволяет выбрать оптимальную тактику лечения и улучшить качество оказания медицинской помощи.
Ключевые слова: гастроэзофагеальная рефлюксная болезнь, ингибиторы протонной помпы, эзомепразол, пищевод Барретта, неэрозивная рефлюксная болезнь.
________________________________________________
Main points. Gastro-esophageal reflux disease occupies the leading position among the gastrointestinal tract disorders. Its prevalence in the Russian Federation is 18–46%. Patients with characteristic clinical symptoms require esophagogastroduodenoscopy with biopsy of the esophageal mucosa to verify the form of GERD and to exclude foci of intestinal metaplasia and dysplasia. In addition, diagnostic approaches include 24-hour pH-impedancemetry and esophagus manometry which allow you not only to exclude functional heartburn but also to prescribe an individualized therapy based on a nature of an refluxate and motor disorders. Proton pump inhibitors (PPI) are the drugs of choice for a treatment of all forms of GERD. Esomeprazole has demonstrated efficacy in a treatment of non-erosive reflux disease, erosive reflux esophagitis and refractory course of the disease. In addition, esomeprazole is used for maintenance therapy of GERD. Surgical treatment of patients with GERD should be carried out following a meticulous examination and according to strict indications.
Conclusion. The results of treatment and prevention of GERD complications are determined by a proper timely diagnosis of the disease, given individual characteristics of each patient. This allows you to choose the optimal treatment tactics and to improve a quality of medical care.
Key words: gastro-esophageal reflux disease, proton pump inhibitors, esomeprazole, Barrett’s esophagus, non-erosive reflux disease
Полный текст
Список литературы
1. Ивашкин В.Т., Трухманов А.С. Болезни пищевода. М.: Триада-X, 2000.
[Ivashkin V.T., Trukhmanov A.S. Bolezni pishchevoda. Moscow: Triada-X, 2000 (in Russian).]
2. Ивашкин В.Т., Маев И.В., Трухманов А.С. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2017; 27 (4): 75–95.
[Ivashkin V.T., Maev I.V., Trukhmanov A.S. i dr. Klinicheskie rekomendatsii Rossiiskoi gastroenterologicheskoi assotsiatsii po diagnostike i lecheniiu gastroezofageal'noi refliuksnoi bolezni. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2017; 27 (4): 75–95 (in Russian).]
3. Shaheen NJ, Hansen RA, Morgan DR et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol 2006; 101: 2128–38.
4. Carlsson R, Galmiche JP, Dent J et al. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 1997; 11: 473–82.
5. Vakil NB, Shaker R, Johnson DA et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001; 15: 927–35.
6. Bytzer P, van Zanten SV, Mattsson H, Wernersson B. Partial symptomresponse to proton pump inhibitors in patients with nonerosive reflux disease or reflux oesophagitis – a post hoc analysis of 5796 patients. Aliment Pharmacol Ther 2012; 36: 635–43.
7. Cicala M, Emerenziani S, Guarino MP, Ribolsi M. Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease. World J Gastroenterol 2013; 19 (39): 6529–35.
8. Ивашкин В.Т., Маев И.В., Трухманов А.С. и др. Гастроэзофагеальная рефлюксная болезнь. Клинические рекомендации. М., 2014.
[Ivashkin V.T., Maev I.V., Trukhmanov A.S. et al. Gastroezofageal'naia refliuksnaia bolezn'. Klinicheskie rekomendatsii. Moscow, 2014 (in Russian).]
9. Karamanolis Georgios P, Sifrim D. Patients with refractory gastroesophageal reflux disease: diagnostic tools. Ann Gastroenterol 2013; 26 (1): 6–10.
10. Трухманов А.С, Сторонова О.А., Ивашкин В.Т. Клиническое значение исследования двигательной функции пищеварительной системы: прошлое, настоящее, будущее. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2013; 23 (5): 4–14.
[Trukhmanov A.S, Storonova O.A., Ivashkin V.T. Klinicheskoe znachenie issledovaniia dvigatel'noi funktsii pishchevaritel'noi sistemy: proshloe, nastoiashchee, budushchee. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2013; 23 (5): 4–14 (in Russian).]
11. Ивашкин В.Т., Трухманов А.С. Эволюция представлений о роли нарушений двигательной функции пищевода в патогенезе гастроэзофагеальной рефлюксной болезни. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2010; 20 (2): 13–9.
[Ivashkin V.T., Trukhmanov A.S. Evoliutsiia predstavlenii o roli narushenii dvigatel'noi funktsii pishchevoda v patogeneze gastroezofageal'noi refliuksnoi bolezni. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2010; 20 (2): 13–9 (in Russian).]
12. Сторонова О.А., Трухманов А.С., Джахая Н.Л., Ивашкин В.Т. Нарушения пищеводного клиренса при гастроэзофагеальной рефлюксной болезни и возможности их коррекции. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2012; 21 (2): 14–21.
[Storonova O.A., Trukhmanov A.S., Dzhakhaia N.L., Ivashkin V.T. Narusheniia pishchevodnogo klirensa pri gastroezofageal'noi refliuksnoi bolezni i vozmozhnosti ikh korrektsii. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2012; 21 (2): 14–21 (in Russian).]
13. Boeckxstaens GE. Alterations confined to the gastro-oesophageal junction: therelationship between low LOSP, TLOSRs, hiatus hernia and acid pocket. Best Pract Res Clin Gastroenterol 2010; 24: 821–9.
14. Tsoukali E, Sifrim D. Investigation of extraesophageal gastroesophageal reflux disease. Ann Gastroenterol 2013; 26 (4): 290–5.
15. Wu JC, Mui LM, Cheung CM et al. Obesity is associated with increased transient lower esophageal sphincter relaxation. Digestion 2007; 132 (3): 883–9.
16. Kahrilas PJ, McColl K, Fox M et al. The acid pocket: a target for treatment in reflux disease? Am J Gastroenterol 2013; 108: 1058–64.
17. Маев И.В., Самсонов А.А., Андреев Д.Н. Роль и место антацидов в современных алгоритмах терапии кислотозависимых заболеваний. Фарматека. 2013; 2: 66–72.
[Maev I.V., Samsonov A.A., Andreev D.N. Rol' i mesto antatsidov v sovremennykh algoritmakh terapii kislotozavisimykh zabolevanii. Farmateka. 2013; 2: 66–72 (in Russian).]
18. Fletcher J, Wirz A, Young J et al. Unbuffered highly acidic gastriс juice exists at the gastroesophageal junction after a meal. Gastroenterology 2001; 121 (4): 775–83.
19. Ивашкин В.Т., Трухманов А.С. Современный подход к терапии гастроэзофагеальной рефлюксной болезни во врачебной практике. Рус. мед. журн. Болезни органов пищеварения. 2003; 5 (2): 43.
[Ivashkin V.T., Trukhmanov A.S. Sovremennyi podkhod k terapii gastroezofageal'noi refliuksnoi bolezni vo vrachebnoi praktike. Rus. med. zhurn. Bolezni organov pishchevareniia. 2003; 5 (2): 43 (in Russian).]
20. Ивашкин В.Т., Маев И.В., Трухманов А.С. Пищевод Баррета. В 2 т. М.: Шико, 2011.
[Ivashkin V.T., Maev I.V., Trukhmanov A.S. Pishchevod Barreta. V 2 t. Moscow: Shiko, 2011 (in Russian).]
21. Ивашкин В.Т., Маев И.В., Трухманов А.С. и др. Манометрия высокого разрешения и новая классификация нарушений моторики пищевода. Терапевтический архив. 2018; 5: 93–100.
[Ivashkin V.T., Maev I.V., Trukhmanov A.S. et al. Manometriia vysokogo razresheniia i novaia klassifikatsiia narushenii motoriki pishchevoda. Therapeutic Archive. 2018; 5: 93–100 (in Russian).]
22. Маев И.В., Баркалова Е.В., Овсепян М.А. и др. Возможности рН-импедансометрии и манометрии высокого разрешения при ведении пациентов с рефрактерной гастроэзофагеальной рефлюксной болезнью. Терапевтический архив. 2017; 89 (2): 76–83.
[Maev I.V., Barkalova E.V., Ovsepian M.A. et al. Vozmozhnosti rN-impedansometrii i manometrii vysokogo razresheniia pri vedenii patsientov s refrakternoi gastroezofageal'noi refliuksnoi bolezn'iu. Therapeutic Archive. 2017; 89 (2): 76–83 (in Russian).]
23. Трухманов А.С. Диагностика и лечение гастроэзофагеальной рефлюксной болезни. Терапевтический архив. 2011; 83 (8): 44–8.
[Trukhmanov A.S. Diagnostika i lechenie gastroezofageal'noi refliuksnoi bolezni. Therapeutic Archive. 2011; 83 (8): 44–8 (in Russian).]
24. Трухманов А.С., Сторонова О.А., Ивашкин В.Т. Клиническое значение исследования двигательной функции пищеварительной системы: прошлое, настоящее, будущее. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2013; 23 (5):
4–14.
[Trukhmanov A.S., Storonova O.A., Ivashkin V.T. Klinicheskoe znachenie issledovaniia dvigatel'noi funktsii pishchevaritel'noi sistemy: proshloe, nastoiashchee, budushchee. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2013; 23 (5): 4–14 (in Russian).]
25. Rohof WOA, Bredenoord AJ. Chicago Classification of Esophageal Motility Disorders: Lessons Learned. Curr Gastroenterol Rep 2017; 19 (8): 37.
26. Shaker A, Stoikes N, Drapekin J et al. Multiple Rapid Swallow Responses During Esophageal High-Resolution Manometry Reflect Esophageal Body Peristaltic Reserve. Am J Gastroenterol 2013; 108 (11): 1706–12.
27. Трухманов А.С., Сторонова О.А., Ивашкин В.Т. Клиническое значение 24-часовой рН-метрии в диагностике и оценке эффективности лекарственных препаратов у больных с заболеваниями пищевода и желудка. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2016; 26 (6): 55–68.
[Trukhmanov A.S., Storonova O.A., Ivashkin V.T. Klinicheskoe znachenie 24-chasovoi rN-metrii v diagnostike i otsenke effektivnosti lekarstvennykh preparatov u bol'nykh s zabolevaniiami pishchevoda i zheludka. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2016; 26 (6): 55–68 (in Russian).]
28. Кайбышева В.О., Сторонова О.А., Трухманов А.С., Ивашкин В.Т. Внутрипищеводная рН-импедансометрия в диагностике ГЭРБ. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2013; 2: 4–12.
[Kaibysheva V.O., Storonova O.A., Trukhmanov A.S., Ivashkin V.T. Vnutripishchevodnaia rN-impedansometriia v diagnostike GERB. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2013; 2: 4–12 (in Russian).]
29. Sifrim D, Fornari F. Esophageal impedance-pH monitoring. Dig Liver Dis 2008; 40: 161–6.
30. Villa N, Vela MF. Impedance-pH testing. Gastroenterol Clin N Am 2013; 42: 17–26.
31. Martinucci I, de Bortoli N, Savarino E et al. Esophageal baseline impedance levels in patients with pathophysiological characteristics of functional heartburn. Neurogastroenterol Motil 2014; 26: 546–55.
32. Frazzoni L, Frazzoni M, de Bortoli N et al. Critical appraisal of Rome IV criteria: hypersensitive esophagus does belong to gastroesophageal reflux disease spectrum. Ann Gastroenterol 2018; 31 (1): 1–7.
33. El-Serag HB, Ergun GA, Pandolfino J et al. Obesity increases oesophageal acid exposure. Gut 2007; 56: 749–55.
34. Wu JC, Lai LH, Chow DK et al. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease. Neurogastroenterol Motil 2011; 23 (2): 155–60.
35. Piesman M, Hwang I, Maydonovitch C. Nocturnal reflux episodes following the administration of a standardized meal. Does timing matter? Am J Gastroenterol 2007; 102: 2128–34.
36. Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006; 166: 965–71.
37. Stanciu C, Bennett JR. Effects of posture on gastrooesophageal reflux. Digestion 1977; 15: 104–9.
38. Sigterman KE, van Pinxteren B, Bonis PA. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastrooesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2013; 5: CD002095.
39. Gunaratnam NT, Jessup TP, Inadomi J. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastrooesophageal reflux disease. Aliment Pharmacol Ther 2006; 23: 1473–7.
40. Johnson DA, Lauritsen K, Junghard O, Levine D. Evaluation of symptoms is an unreliable predictor of relapse of erosive esophagitis in patients receiving maintenance PPI therapy. Gastroenterology 2003; 124 (4; Suppl. 1): A540.
41. Chey WD, Inadomi JM, Booher AM et al. Primary-care physicians’ perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol 2005; 100 (6): 1237–42.
42. Boltin D, Zvidi I, Raskin M et al. Effect of Postprandial Administration of Esomeprazole on Reflux Symptoms in Gastroesophageal Reflux Disease: A Randomized, Controlled Trial. Dig Dis 2018.
43. Talley NJ, Lauritsen K, Tunturi-Hihnala H et al. Esomeprazole 20 mg maintain symptom control in endoscopy-negative gastro-esophageal reflux disease: a controlled trial of ‘on-demand’ therapy for 6 months. Aliment Pharmacol Ther 2001; 15: 347–54.
44. Bayerdörffer E, Bigard Marc-Andre, Weiss W et al. Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease. BMC Gastroenterology 2016; 16: 48.
45. Lind T, Rydberg L, Kylebaeck A et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 861–7.
46. Andersson Т, Rohss K, Hassan-Alin M, Bredberg E. Pharmacokinetics and dose-response relationship of esomeprasole. Gastroenterology 2000; 118: A1210.
47. Castell D, Castell D, Kahrilas P et al. Esomeprazole provides more effective healing than lansoprazole in GERD patients with erosive oesophagitis. Gut 2001; 49 (Suppl. U): A3363.
48. Kahrilas P, Falk J, Johnson D et al. Esomeprazole improves healing and symptom reso-lution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 2000; 14: 1249–58.
49. Richter J, Kahrilas P, Johanson J. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive oesophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656–65.
50. Rohss K, Wilder-Smith C, Claar-Nilsson С et al. Esomeprazole 40 mg provides more effective acid control than standard doses of all other proton pump inhibitors. Gastroenterology 2001; 120: A2140.
51. Wilder-Smith C, Rohss K, Lundin C, Rydholm H. Esomeprazole 40 mg provides more effective acid control than pantoprazole 40 mg. Gastroenterology 2000; 118: A22.
52. Edwards S, Lind Т, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux eosophagitis. Aliment Pharmacol Ther 2001; 15: 1729–36.
53. Li Mei-Juan, Li Qing, Sun Min, Liu Li-Qin. Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis. A PRISMA-compliant network meta-analysis. Medicine 2017; 96: 39.
54. Евсютина Ю.В., Трухманов А.С. Новый взгляд на проблему гастроэзофагеальной рефлюксной болезни, рефрактерной к лечению ингибиторами протонной помпы. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2014; 5: 4–9.
[Evsiutina Iu.V., Trukhmanov A.S. Novyi vzgliad na problemu gastroezofageal'noi refliuksnoi bolezni, refrakternoi k lecheniiu ingibitorami protonnoi pompy. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2014; 5: 4–9 (in Russian).]
55. Маев И.В., Самсонов А.А., Андреев Д.Н. Роль и место антацидов в современных алгоритмах терапии кислотозависимых заболеваний. Фарматека. 2013; 2: 66–72.
[Maev I.V., Samsonov A.A., Andreev D.N. Rol' i mesto antatsidov v sovremennykh algoritmakh terapii kislotozavisimykh zabolevanii. Farmateka. 2013; 2: 66–72 (in Russian).]
56. Wilder-Smith C, Rohss K, Lundin C, Rydholm H. Esomeprazole 40 mg provides more effective acid control than pantoprazole 40 mg. Gastroenterology 2000; 118: A22.
57. Ивашкин В.Т., Маев И.В., Трухманов А.С. и др. Пищевод Баррета. Клинические рекомендации. Российская гастроэнтерологическая ассоциация. М., 2014.
[Ivashkin V.T., Maev I.V., Trukhmanov A.S. et al. Pishchevod Barreta. Klinicheskie rekomendatsii. Rossiiskaia gastroenterologicheskaia assotsiatsiia. Moscow, 2014 (in Russian).]
58. Galmiche JP, Hatlebakk J, Attwood S et al. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA 2011; 305: 1969–77.
2. Ivashkin V.T., Maev I.V., Trukhmanov A.S. i dr. Klinicheskie rekomendatsii Rossiiskoi gastroenterologicheskoi assotsiatsii po diagnostike i lecheniiu gastroezofageal'noi refliuksnoi bolezni. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2017; 27 (4): 75–95 (in Russian).
3. Shaheen NJ, Hansen RA, Morgan DR et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol 2006; 101: 2128–38.
4. Carlsson R, Galmiche JP, Dent J et al. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 1997; 11: 473–82.
5. Vakil NB, Shaker R, Johnson DA et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001; 15: 927–35.
6. Bytzer P, van Zanten SV, Mattsson H, Wernersson B. Partial symptomresponse to proton pump inhibitors in patients with nonerosive reflux disease or reflux oesophagitis – a post hoc analysis of 5796 patients. Aliment Pharmacol Ther 2012; 36: 635–43.
7. Cicala M, Emerenziani S, Guarino MP, Ribolsi M. Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease. World J Gastroenterol 2013; 19 (39): 6529–35.
8. Ivashkin V.T., Maev I.V., Trukhmanov A.S. et al. Gastroezofageal'naia refliuksnaia bolezn'. Klinicheskie rekomendatsii. Moscow, 2014 (in Russian).
9. Karamanolis Georgios P, Sifrim D. Patients with refractory gastroesophageal reflux disease: diagnostic tools. Ann Gastroenterol 2013; 26 (1): 6–10.
10. Trukhmanov A.S, Storonova O.A., Ivashkin V.T. Klinicheskoe znachenie issledovaniia dvigatel'noi funktsii pishchevaritel'noi sistemy: proshloe, nastoiashchee, budushchee. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2013; 23 (5): 4–14 (in Russian).
11. Ivashkin V.T., Trukhmanov A.S. Evoliutsiia predstavlenii o roli narushenii dvigatel'noi funktsii pishchevoda v patogeneze gastroezofageal'noi refliuksnoi bolezni. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2010; 20 (2): 13–9 (in Russian).
12. Storonova O.A., Trukhmanov A.S., Dzhakhaia N.L., Ivashkin V.T. Narusheniia pishchevodnogo klirensa pri gastroezofageal'noi refliuksnoi bolezni i vozmozhnosti ikh korrektsii. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2012; 21 (2): 14–21 (in Russian).
13. Boeckxstaens GE. Alterations confined to the gastro-oesophageal junction: therelationship between low LOSP, TLOSRs, hiatus hernia and acid pocket. Best Pract Res Clin Gastroenterol 2010; 24: 821–9.
14. Tsoukali E, Sifrim D. Investigation of extraesophageal gastroesophageal reflux disease. Ann Gastroenterol 2013; 26 (4): 290–5.
15. Wu JC, Mui LM, Cheung CM et al. Obesity is associated with increased transient lower esophageal sphincter relaxation. Digestion 2007; 132 (3): 883–9.
16. Kahrilas PJ, McColl K, Fox M et al. The acid pocket: a target for treatment in reflux disease? Am J Gastroenterol 2013; 108: 1058–64.
17. Маев И.В., Самсонов А.А., Андреев Д.Н. Роль и место антацидов в современных алгоритмах терапии кислотозависимых заболеваний. Фарматека. 2013; 2: 66–72.
[Maev I.V., Samsonov A.A., Andreev D.N. Rol' i mesto antatsidov v sovremennykh algoritmakh terapii kislotozavisimykh zabolevanii. Farmateka. 2013; 2: 66–72 (in Russian).]
18. Fletcher J, Wirz A, Young J et al. Unbuffered highly acidic gastriс juice exists at the gastroesophageal junction after a meal. Gastroenterology 2001; 121 (4): 775–83.
19.Ivashkin V.T., Trukhmanov A.S. Sovremennyi podkhod k terapii gastroezofageal'noi refliuksnoi bolezni vo vrachebnoi praktike. Rus. med. zhurn. Bolezni organov pishchevareniia. 2003; 5 (2): 43 (in Russian).
20. Ivashkin V.T., Maev I.V., Trukhmanov A.S. Pishchevod Barreta. V 2 t. Moscow: Shiko, 2011 (in Russian).
21.Ivashkin V.T., Maev I.V., Trukhmanov A.S. et al. Manometriia vysokogo razresheniia i novaia klassifikatsiia narushenii motoriki pishchevoda. Therapeutic Archive. 2018; 5: 93–100 (in Russian).
22. Maev I.V., Barkalova E.V., Ovsepian M.A. et al. Vozmozhnosti rN-impedansometrii i manometrii vysokogo razresheniia pri vedenii patsientov s refrakternoi gastroezofageal'noi refliuksnoi bolezn'iu. Therapeutic Archive. 2017; 89 (2): 76–83 (in Russian).
23. Trukhmanov A.S. Diagnostika i lechenie gastroezofageal'noi refliuksnoi bolezni. Therapeutic Archive. 2011; 83 (8): 44–8 (in Russian).
24. Trukhmanov A.S., Storonova O.A., Ivashkin V.T. Klinicheskoe znachenie issledovaniia dvigatel'noi funktsii pishchevaritel'noi sistemy: proshloe, nastoiashchee, budushchee. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2013; 23 (5): 4–14 (in Russian).
25. Rohof WOA, Bredenoord AJ. Chicago Classification of Esophageal Motility Disorders: Lessons Learned. Curr Gastroenterol Rep 2017; 19 (8): 37.
26. Shaker A, Stoikes N, Drapekin J et al. Multiple Rapid Swallow Responses During Esophageal High-Resolution Manometry Reflect Esophageal Body Peristaltic Reserve. Am J Gastroenterol 2013; 108 (11): 1706–12.
27. Trukhmanov A.S., Storonova O.A., Ivashkin V.T. Klinicheskoe znachenie 24-chasovoi rN-metrii v diagnostike i otsenke effektivnosti lekarstvennykh preparatov u bol'nykh s zabolevaniiami pishchevoda i zheludka. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2016; 26 (6): 55–68 (in Russian).
28. Kaibysheva V.O., Storonova O.A., Trukhmanov A.S., Ivashkin V.T. Vnutripishchevodnaia rN-impedansometriia v diagnostike GERB. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2013; 2: 4–12 (in Russian).
29. Sifrim D, Fornari F. Esophageal impedance-pH monitoring. Dig Liver Dis 2008; 40: 161–6.
30. Villa N, Vela MF. Impedance-pH testing. Gastroenterol Clin N Am 2013; 42: 17–26.
31. Martinucci I, de Bortoli N, Savarino E et al. Esophageal baseline impedance levels in patients with pathophysiological characteristics of functional heartburn. Neurogastroenterol Motil 2014; 26: 546–55.
32. Frazzoni L, Frazzoni M, de Bortoli N et al. Critical appraisal of Rome IV criteria: hypersensitive esophagus does belong to gastroesophageal reflux disease spectrum. Ann Gastroenterol 2018; 31 (1): 1–7.
33. El-Serag HB, Ergun GA, Pandolfino J et al. Obesity increases oesophageal acid exposure. Gut 2007; 56: 749–55.
34. Wu JC, Lai LH, Chow DK et al. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease. Neurogastroenterol Motil 2011; 23 (2): 155–60.
35. Piesman M, Hwang I, Maydonovitch C. Nocturnal reflux episodes following the administration of a standardized meal. Does timing matter? Am J Gastroenterol 2007; 102: 2128–34.
36. Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006; 166: 965–71.
37. Stanciu C, Bennett JR. Effects of posture on gastrooesophageal reflux. Digestion 1977; 15: 104–9.
38. Sigterman KE, van Pinxteren B, Bonis PA. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastrooesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2013; 5: CD002095.
39. Gunaratnam NT, Jessup TP, Inadomi J. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastrooesophageal reflux disease. Aliment Pharmacol Ther 2006; 23: 1473–7.
40. Johnson DA, Lauritsen K, Junghard O, Levine D. Evaluation of symptoms is an unreliable predictor of relapse of erosive esophagitis in patients receiving maintenance PPI therapy. Gastroenterology 2003; 124 (4; Suppl. 1): A540.
41. Chey WD, Inadomi JM, Booher AM et al. Primary-care physicians’ perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol 2005; 100 (6): 1237–42.
42. Boltin D, Zvidi I, Raskin M et al. Effect of Postprandial Administration of Esomeprazole on Reflux Symptoms in Gastroesophageal Reflux Disease: A Randomized, Controlled Trial. Dig Dis 2018.
43. Talley NJ, Lauritsen K, Tunturi-Hihnala H et al. Esomeprazole 20 mg maintain symptom control in endoscopy-negative gastro-esophageal reflux disease: a controlled trial of ‘on-demand’ therapy for 6 months. Aliment Pharmacol Ther 2001; 15: 347–54.
44. Bayerdörffer E, Bigard Marc-Andre, Weiss W et al. Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease. BMC Gastroenterology 2016; 16: 48.
45. Lind T, Rydberg L, Kylebaeck A et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 861–7.
46. Andersson Т, Rohss K, Hassan-Alin M, Bredberg E. Pharmacokinetics and dose-response relationship of esomeprasole. Gastroenterology 2000; 118: A1210.
47. Castell D, Castell D, Kahrilas P et al. Esomeprazole provides more effective healing than lansoprazole in GERD patients with erosive oesophagitis. Gut 2001; 49 (Suppl. U): A3363.
48. Kahrilas P, Falk J, Johnson D et al. Esomeprazole improves healing and symptom reso-lution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 2000; 14: 1249–58.
49. Richter J, Kahrilas P, Johanson J. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive oesophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656–65.
50. Rohss K, Wilder-Smith C, Claar-Nilsson С et al. Esomeprazole 40 mg provides more effective acid control than standard doses of all other proton pump inhibitors. Gastroenterology 2001; 120: A2140.
51. Wilder-Smith C, Rohss K, Lundin C, Rydholm H. Esomeprazole 40 mg provides more effective acid control than pantoprazole 40 mg. Gastroenterology 2000; 118: A22.
52. Edwards S, Lind Т, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux eosophagitis. Aliment Pharmacol Ther 2001; 15: 1729–36.
53. Li Mei-Juan, Li Qing, Sun Min, Liu Li-Qin. Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis. A PRISMA-compliant network meta-analysis. Medicine 2017; 96: 39.
54. Evsiutina Iu.V., Trukhmanov A.S. Novyi vzgliad na problemu gastroezofageal'noi refliuksnoi bolezni, refrakternoi k lecheniiu ingibitorami protonnoi pompy. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2014; 5: 4–9 (in Russian).
55. Maev I.V., Samsonov A.A., Andreev D.N. Rol' i mesto antatsidov v sovremennykh algoritmakh terapii kislotozavisimykh zabolevanii. Farmateka. 2013; 2: 66–72 (in Russian).
56. Wilder-Smith C, Rohss K, Lundin C, Rydholm H. Esomeprazole 40 mg provides more effective acid control than pantoprazole 40 mg. Gastroenterology 2000; 118: A22.
57. Ivashkin V.T., Maev I.V., Trukhmanov A.S. et al. Pishchevod Barreta. Klinicheskie rekomendatsii. Rossiiskaia gastroenterologicheskaia assotsiatsiia. Moscow, 2014 (in Russian).
58. Galmiche JP, Hatlebakk J, Attwood S et al. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA 2011; 305: 1969–77.
[Ivashkin V.T., Trukhmanov A.S. Bolezni pishchevoda. Moscow: Triada-X, 2000 (in Russian).]
2. Ивашкин В.Т., Маев И.В., Трухманов А.С. и др. Клинические рекомендации Российской гастроэнтерологической ассоциации по диагностике и лечению гастроэзофагеальной рефлюксной болезни. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2017; 27 (4): 75–95.
[Ivashkin V.T., Maev I.V., Trukhmanov A.S. i dr. Klinicheskie rekomendatsii Rossiiskoi gastroenterologicheskoi assotsiatsii po diagnostike i lecheniiu gastroezofageal'noi refliuksnoi bolezni. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2017; 27 (4): 75–95 (in Russian).]
3. Shaheen NJ, Hansen RA, Morgan DR et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol 2006; 101: 2128–38.
4. Carlsson R, Galmiche JP, Dent J et al. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 1997; 11: 473–82.
5. Vakil NB, Shaker R, Johnson DA et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001; 15: 927–35.
6. Bytzer P, van Zanten SV, Mattsson H, Wernersson B. Partial symptomresponse to proton pump inhibitors in patients with nonerosive reflux disease or reflux oesophagitis – a post hoc analysis of 5796 patients. Aliment Pharmacol Ther 2012; 36: 635–43.
7. Cicala M, Emerenziani S, Guarino MP, Ribolsi M. Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease. World J Gastroenterol 2013; 19 (39): 6529–35.
8. Ивашкин В.Т., Маев И.В., Трухманов А.С. и др. Гастроэзофагеальная рефлюксная болезнь. Клинические рекомендации. М., 2014.
[Ivashkin V.T., Maev I.V., Trukhmanov A.S. et al. Gastroezofageal'naia refliuksnaia bolezn'. Klinicheskie rekomendatsii. Moscow, 2014 (in Russian).]
9. Karamanolis Georgios P, Sifrim D. Patients with refractory gastroesophageal reflux disease: diagnostic tools. Ann Gastroenterol 2013; 26 (1): 6–10.
10. Трухманов А.С, Сторонова О.А., Ивашкин В.Т. Клиническое значение исследования двигательной функции пищеварительной системы: прошлое, настоящее, будущее. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2013; 23 (5): 4–14.
[Trukhmanov A.S, Storonova O.A., Ivashkin V.T. Klinicheskoe znachenie issledovaniia dvigatel'noi funktsii pishchevaritel'noi sistemy: proshloe, nastoiashchee, budushchee. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2013; 23 (5): 4–14 (in Russian).]
11. Ивашкин В.Т., Трухманов А.С. Эволюция представлений о роли нарушений двигательной функции пищевода в патогенезе гастроэзофагеальной рефлюксной болезни. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2010; 20 (2): 13–9.
[Ivashkin V.T., Trukhmanov A.S. Evoliutsiia predstavlenii o roli narushenii dvigatel'noi funktsii pishchevoda v patogeneze gastroezofageal'noi refliuksnoi bolezni. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2010; 20 (2): 13–9 (in Russian).]
12. Сторонова О.А., Трухманов А.С., Джахая Н.Л., Ивашкин В.Т. Нарушения пищеводного клиренса при гастроэзофагеальной рефлюксной болезни и возможности их коррекции. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2012; 21 (2): 14–21.
[Storonova O.A., Trukhmanov A.S., Dzhakhaia N.L., Ivashkin V.T. Narusheniia pishchevodnogo klirensa pri gastroezofageal'noi refliuksnoi bolezni i vozmozhnosti ikh korrektsii. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2012; 21 (2): 14–21 (in Russian).]
13. Boeckxstaens GE. Alterations confined to the gastro-oesophageal junction: therelationship between low LOSP, TLOSRs, hiatus hernia and acid pocket. Best Pract Res Clin Gastroenterol 2010; 24: 821–9.
14. Tsoukali E, Sifrim D. Investigation of extraesophageal gastroesophageal reflux disease. Ann Gastroenterol 2013; 26 (4): 290–5.
15. Wu JC, Mui LM, Cheung CM et al. Obesity is associated with increased transient lower esophageal sphincter relaxation. Digestion 2007; 132 (3): 883–9.
16. Kahrilas PJ, McColl K, Fox M et al. The acid pocket: a target for treatment in reflux disease? Am J Gastroenterol 2013; 108: 1058–64.
17. Маев И.В., Самсонов А.А., Андреев Д.Н. Роль и место антацидов в современных алгоритмах терапии кислотозависимых заболеваний. Фарматека. 2013; 2: 66–72.
[Maev I.V., Samsonov A.A., Andreev D.N. Rol' i mesto antatsidov v sovremennykh algoritmakh terapii kislotozavisimykh zabolevanii. Farmateka. 2013; 2: 66–72 (in Russian).]
18. Fletcher J, Wirz A, Young J et al. Unbuffered highly acidic gastriс juice exists at the gastroesophageal junction after a meal. Gastroenterology 2001; 121 (4): 775–83.
19. Ивашкин В.Т., Трухманов А.С. Современный подход к терапии гастроэзофагеальной рефлюксной болезни во врачебной практике. Рус. мед. журн. Болезни органов пищеварения. 2003; 5 (2): 43.
[Ivashkin V.T., Trukhmanov A.S. Sovremennyi podkhod k terapii gastroezofageal'noi refliuksnoi bolezni vo vrachebnoi praktike. Rus. med. zhurn. Bolezni organov pishchevareniia. 2003; 5 (2): 43 (in Russian).]
20. Ивашкин В.Т., Маев И.В., Трухманов А.С. Пищевод Баррета. В 2 т. М.: Шико, 2011.
[Ivashkin V.T., Maev I.V., Trukhmanov A.S. Pishchevod Barreta. V 2 t. Moscow: Shiko, 2011 (in Russian).]
21. Ивашкин В.Т., Маев И.В., Трухманов А.С. и др. Манометрия высокого разрешения и новая классификация нарушений моторики пищевода. Терапевтический архив. 2018; 5: 93–100.
[Ivashkin V.T., Maev I.V., Trukhmanov A.S. et al. Manometriia vysokogo razresheniia i novaia klassifikatsiia narushenii motoriki pishchevoda. Therapeutic Archive. 2018; 5: 93–100 (in Russian).]
22. Маев И.В., Баркалова Е.В., Овсепян М.А. и др. Возможности рН-импедансометрии и манометрии высокого разрешения при ведении пациентов с рефрактерной гастроэзофагеальной рефлюксной болезнью. Терапевтический архив. 2017; 89 (2): 76–83.
[Maev I.V., Barkalova E.V., Ovsepian M.A. et al. Vozmozhnosti rN-impedansometrii i manometrii vysokogo razresheniia pri vedenii patsientov s refrakternoi gastroezofageal'noi refliuksnoi bolezn'iu. Therapeutic Archive. 2017; 89 (2): 76–83 (in Russian).]
23. Трухманов А.С. Диагностика и лечение гастроэзофагеальной рефлюксной болезни. Терапевтический архив. 2011; 83 (8): 44–8.
[Trukhmanov A.S. Diagnostika i lechenie gastroezofageal'noi refliuksnoi bolezni. Therapeutic Archive. 2011; 83 (8): 44–8 (in Russian).]
24. Трухманов А.С., Сторонова О.А., Ивашкин В.Т. Клиническое значение исследования двигательной функции пищеварительной системы: прошлое, настоящее, будущее. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2013; 23 (5):
4–14.
[Trukhmanov A.S., Storonova O.A., Ivashkin V.T. Klinicheskoe znachenie issledovaniia dvigatel'noi funktsii pishchevaritel'noi sistemy: proshloe, nastoiashchee, budushchee. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2013; 23 (5): 4–14 (in Russian).]
25. Rohof WOA, Bredenoord AJ. Chicago Classification of Esophageal Motility Disorders: Lessons Learned. Curr Gastroenterol Rep 2017; 19 (8): 37.
26. Shaker A, Stoikes N, Drapekin J et al. Multiple Rapid Swallow Responses During Esophageal High-Resolution Manometry Reflect Esophageal Body Peristaltic Reserve. Am J Gastroenterol 2013; 108 (11): 1706–12.
27. Трухманов А.С., Сторонова О.А., Ивашкин В.Т. Клиническое значение 24-часовой рН-метрии в диагностике и оценке эффективности лекарственных препаратов у больных с заболеваниями пищевода и желудка. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2016; 26 (6): 55–68.
[Trukhmanov A.S., Storonova O.A., Ivashkin V.T. Klinicheskoe znachenie 24-chasovoi rN-metrii v diagnostike i otsenke effektivnosti lekarstvennykh preparatov u bol'nykh s zabolevaniiami pishchevoda i zheludka. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2016; 26 (6): 55–68 (in Russian).]
28. Кайбышева В.О., Сторонова О.А., Трухманов А.С., Ивашкин В.Т. Внутрипищеводная рН-импедансометрия в диагностике ГЭРБ. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2013; 2: 4–12.
[Kaibysheva V.O., Storonova O.A., Trukhmanov A.S., Ivashkin V.T. Vnutripishchevodnaia rN-impedansometriia v diagnostike GERB. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2013; 2: 4–12 (in Russian).]
29. Sifrim D, Fornari F. Esophageal impedance-pH monitoring. Dig Liver Dis 2008; 40: 161–6.
30. Villa N, Vela MF. Impedance-pH testing. Gastroenterol Clin N Am 2013; 42: 17–26.
31. Martinucci I, de Bortoli N, Savarino E et al. Esophageal baseline impedance levels in patients with pathophysiological characteristics of functional heartburn. Neurogastroenterol Motil 2014; 26: 546–55.
32. Frazzoni L, Frazzoni M, de Bortoli N et al. Critical appraisal of Rome IV criteria: hypersensitive esophagus does belong to gastroesophageal reflux disease spectrum. Ann Gastroenterol 2018; 31 (1): 1–7.
33. El-Serag HB, Ergun GA, Pandolfino J et al. Obesity increases oesophageal acid exposure. Gut 2007; 56: 749–55.
34. Wu JC, Lai LH, Chow DK et al. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease. Neurogastroenterol Motil 2011; 23 (2): 155–60.
35. Piesman M, Hwang I, Maydonovitch C. Nocturnal reflux episodes following the administration of a standardized meal. Does timing matter? Am J Gastroenterol 2007; 102: 2128–34.
36. Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006; 166: 965–71.
37. Stanciu C, Bennett JR. Effects of posture on gastrooesophageal reflux. Digestion 1977; 15: 104–9.
38. Sigterman KE, van Pinxteren B, Bonis PA. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastrooesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2013; 5: CD002095.
39. Gunaratnam NT, Jessup TP, Inadomi J. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastrooesophageal reflux disease. Aliment Pharmacol Ther 2006; 23: 1473–7.
40. Johnson DA, Lauritsen K, Junghard O, Levine D. Evaluation of symptoms is an unreliable predictor of relapse of erosive esophagitis in patients receiving maintenance PPI therapy. Gastroenterology 2003; 124 (4; Suppl. 1): A540.
41. Chey WD, Inadomi JM, Booher AM et al. Primary-care physicians’ perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol 2005; 100 (6): 1237–42.
42. Boltin D, Zvidi I, Raskin M et al. Effect of Postprandial Administration of Esomeprazole on Reflux Symptoms in Gastroesophageal Reflux Disease: A Randomized, Controlled Trial. Dig Dis 2018.
43. Talley NJ, Lauritsen K, Tunturi-Hihnala H et al. Esomeprazole 20 mg maintain symptom control in endoscopy-negative gastro-esophageal reflux disease: a controlled trial of ‘on-demand’ therapy for 6 months. Aliment Pharmacol Ther 2001; 15: 347–54.
44. Bayerdörffer E, Bigard Marc-Andre, Weiss W et al. Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease. BMC Gastroenterology 2016; 16: 48.
45. Lind T, Rydberg L, Kylebaeck A et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 861–7.
46. Andersson Т, Rohss K, Hassan-Alin M, Bredberg E. Pharmacokinetics and dose-response relationship of esomeprasole. Gastroenterology 2000; 118: A1210.
47. Castell D, Castell D, Kahrilas P et al. Esomeprazole provides more effective healing than lansoprazole in GERD patients with erosive oesophagitis. Gut 2001; 49 (Suppl. U): A3363.
48. Kahrilas P, Falk J, Johnson D et al. Esomeprazole improves healing and symptom reso-lution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 2000; 14: 1249–58.
49. Richter J, Kahrilas P, Johanson J. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive oesophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656–65.
50. Rohss K, Wilder-Smith C, Claar-Nilsson С et al. Esomeprazole 40 mg provides more effective acid control than standard doses of all other proton pump inhibitors. Gastroenterology 2001; 120: A2140.
51. Wilder-Smith C, Rohss K, Lundin C, Rydholm H. Esomeprazole 40 mg provides more effective acid control than pantoprazole 40 mg. Gastroenterology 2000; 118: A22.
52. Edwards S, Lind Т, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux eosophagitis. Aliment Pharmacol Ther 2001; 15: 1729–36.
53. Li Mei-Juan, Li Qing, Sun Min, Liu Li-Qin. Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis. A PRISMA-compliant network meta-analysis. Medicine 2017; 96: 39.
54. Евсютина Ю.В., Трухманов А.С. Новый взгляд на проблему гастроэзофагеальной рефлюксной болезни, рефрактерной к лечению ингибиторами протонной помпы. Рос. журн. гастроэнтерологии, гепатологии, колопроктологии. 2014; 5: 4–9.
[Evsiutina Iu.V., Trukhmanov A.S. Novyi vzgliad na problemu gastroezofageal'noi refliuksnoi bolezni, refrakternoi k lecheniiu ingibitorami protonnoi pompy. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2014; 5: 4–9 (in Russian).]
55. Маев И.В., Самсонов А.А., Андреев Д.Н. Роль и место антацидов в современных алгоритмах терапии кислотозависимых заболеваний. Фарматека. 2013; 2: 66–72.
[Maev I.V., Samsonov A.A., Andreev D.N. Rol' i mesto antatsidov v sovremennykh algoritmakh terapii kislotozavisimykh zabolevanii. Farmateka. 2013; 2: 66–72 (in Russian).]
56. Wilder-Smith C, Rohss K, Lundin C, Rydholm H. Esomeprazole 40 mg provides more effective acid control than pantoprazole 40 mg. Gastroenterology 2000; 118: A22.
57. Ивашкин В.Т., Маев И.В., Трухманов А.С. и др. Пищевод Баррета. Клинические рекомендации. Российская гастроэнтерологическая ассоциация. М., 2014.
[Ivashkin V.T., Maev I.V., Trukhmanov A.S. et al. Pishchevod Barreta. Klinicheskie rekomendatsii. Rossiiskaia gastroenterologicheskaia assotsiatsiia. Moscow, 2014 (in Russian).]
58. Galmiche JP, Hatlebakk J, Attwood S et al. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA 2011; 305: 1969–77.
________________________________________________
2. Ivashkin V.T., Maev I.V., Trukhmanov A.S. i dr. Klinicheskie rekomendatsii Rossiiskoi gastroenterologicheskoi assotsiatsii po diagnostike i lecheniiu gastroezofageal'noi refliuksnoi bolezni. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2017; 27 (4): 75–95 (in Russian).
3. Shaheen NJ, Hansen RA, Morgan DR et al. The burden of gastrointestinal and liver diseases, 2006. Am J Gastroenterol 2006; 101: 2128–38.
4. Carlsson R, Galmiche JP, Dent J et al. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long-term omeprazole trials. Aliment Pharmacol Ther 1997; 11: 473–82.
5. Vakil NB, Shaker R, Johnson DA et al. The new proton pump inhibitor esomeprazole is effective as a maintenance therapy in GERD patients with healed erosive oesophagitis: a 6-month, randomized, double-blind, placebo-controlled study of efficacy and safety. Aliment Pharmacol Ther 2001; 15: 927–35.
6. Bytzer P, van Zanten SV, Mattsson H, Wernersson B. Partial symptomresponse to proton pump inhibitors in patients with nonerosive reflux disease or reflux oesophagitis – a post hoc analysis of 5796 patients. Aliment Pharmacol Ther 2012; 36: 635–43.
7. Cicala M, Emerenziani S, Guarino MP, Ribolsi M. Proton pump inhibitor resistance, the real challenge in gastro-esophageal reflux disease. World J Gastroenterol 2013; 19 (39): 6529–35.
8. Ivashkin V.T., Maev I.V., Trukhmanov A.S. et al. Gastroezofageal'naia refliuksnaia bolezn'. Klinicheskie rekomendatsii. Moscow, 2014 (in Russian).
9. Karamanolis Georgios P, Sifrim D. Patients with refractory gastroesophageal reflux disease: diagnostic tools. Ann Gastroenterol 2013; 26 (1): 6–10.
10. Trukhmanov A.S, Storonova O.A., Ivashkin V.T. Klinicheskoe znachenie issledovaniia dvigatel'noi funktsii pishchevaritel'noi sistemy: proshloe, nastoiashchee, budushchee. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2013; 23 (5): 4–14 (in Russian).
11. Ivashkin V.T., Trukhmanov A.S. Evoliutsiia predstavlenii o roli narushenii dvigatel'noi funktsii pishchevoda v patogeneze gastroezofageal'noi refliuksnoi bolezni. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2010; 20 (2): 13–9 (in Russian).
12. Storonova O.A., Trukhmanov A.S., Dzhakhaia N.L., Ivashkin V.T. Narusheniia pishchevodnogo klirensa pri gastroezofageal'noi refliuksnoi bolezni i vozmozhnosti ikh korrektsii. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2012; 21 (2): 14–21 (in Russian).
13. Boeckxstaens GE. Alterations confined to the gastro-oesophageal junction: therelationship between low LOSP, TLOSRs, hiatus hernia and acid pocket. Best Pract Res Clin Gastroenterol 2010; 24: 821–9.
14. Tsoukali E, Sifrim D. Investigation of extraesophageal gastroesophageal reflux disease. Ann Gastroenterol 2013; 26 (4): 290–5.
15. Wu JC, Mui LM, Cheung CM et al. Obesity is associated with increased transient lower esophageal sphincter relaxation. Digestion 2007; 132 (3): 883–9.
16. Kahrilas PJ, McColl K, Fox M et al. The acid pocket: a target for treatment in reflux disease? Am J Gastroenterol 2013; 108: 1058–64.
17. Маев И.В., Самсонов А.А., Андреев Д.Н. Роль и место антацидов в современных алгоритмах терапии кислотозависимых заболеваний. Фарматека. 2013; 2: 66–72.
[Maev I.V., Samsonov A.A., Andreev D.N. Rol' i mesto antatsidov v sovremennykh algoritmakh terapii kislotozavisimykh zabolevanii. Farmateka. 2013; 2: 66–72 (in Russian).]
18. Fletcher J, Wirz A, Young J et al. Unbuffered highly acidic gastriс juice exists at the gastroesophageal junction after a meal. Gastroenterology 2001; 121 (4): 775–83.
19.Ivashkin V.T., Trukhmanov A.S. Sovremennyi podkhod k terapii gastroezofageal'noi refliuksnoi bolezni vo vrachebnoi praktike. Rus. med. zhurn. Bolezni organov pishchevareniia. 2003; 5 (2): 43 (in Russian).
20. Ivashkin V.T., Maev I.V., Trukhmanov A.S. Pishchevod Barreta. V 2 t. Moscow: Shiko, 2011 (in Russian).
21.Ivashkin V.T., Maev I.V., Trukhmanov A.S. et al. Manometriia vysokogo razresheniia i novaia klassifikatsiia narushenii motoriki pishchevoda. Therapeutic Archive. 2018; 5: 93–100 (in Russian).
22. Maev I.V., Barkalova E.V., Ovsepian M.A. et al. Vozmozhnosti rN-impedansometrii i manometrii vysokogo razresheniia pri vedenii patsientov s refrakternoi gastroezofageal'noi refliuksnoi bolezn'iu. Therapeutic Archive. 2017; 89 (2): 76–83 (in Russian).
23. Trukhmanov A.S. Diagnostika i lechenie gastroezofageal'noi refliuksnoi bolezni. Therapeutic Archive. 2011; 83 (8): 44–8 (in Russian).
24. Trukhmanov A.S., Storonova O.A., Ivashkin V.T. Klinicheskoe znachenie issledovaniia dvigatel'noi funktsii pishchevaritel'noi sistemy: proshloe, nastoiashchee, budushchee. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2013; 23 (5): 4–14 (in Russian).
25. Rohof WOA, Bredenoord AJ. Chicago Classification of Esophageal Motility Disorders: Lessons Learned. Curr Gastroenterol Rep 2017; 19 (8): 37.
26. Shaker A, Stoikes N, Drapekin J et al. Multiple Rapid Swallow Responses During Esophageal High-Resolution Manometry Reflect Esophageal Body Peristaltic Reserve. Am J Gastroenterol 2013; 108 (11): 1706–12.
27. Trukhmanov A.S., Storonova O.A., Ivashkin V.T. Klinicheskoe znachenie 24-chasovoi rN-metrii v diagnostike i otsenke effektivnosti lekarstvennykh preparatov u bol'nykh s zabolevaniiami pishchevoda i zheludka. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2016; 26 (6): 55–68 (in Russian).
28. Kaibysheva V.O., Storonova O.A., Trukhmanov A.S., Ivashkin V.T. Vnutripishchevodnaia rN-impedansometriia v diagnostike GERB. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2013; 2: 4–12 (in Russian).
29. Sifrim D, Fornari F. Esophageal impedance-pH monitoring. Dig Liver Dis 2008; 40: 161–6.
30. Villa N, Vela MF. Impedance-pH testing. Gastroenterol Clin N Am 2013; 42: 17–26.
31. Martinucci I, de Bortoli N, Savarino E et al. Esophageal baseline impedance levels in patients with pathophysiological characteristics of functional heartburn. Neurogastroenterol Motil 2014; 26: 546–55.
32. Frazzoni L, Frazzoni M, de Bortoli N et al. Critical appraisal of Rome IV criteria: hypersensitive esophagus does belong to gastroesophageal reflux disease spectrum. Ann Gastroenterol 2018; 31 (1): 1–7.
33. El-Serag HB, Ergun GA, Pandolfino J et al. Obesity increases oesophageal acid exposure. Gut 2007; 56: 749–55.
34. Wu JC, Lai LH, Chow DK et al. Concomitant irritable bowel syndrome is associated with failure of step-down on-demand proton pump inhibitor treatment in patients with gastro-esophageal reflux disease. Neurogastroenterol Motil 2011; 23 (2): 155–60.
35. Piesman M, Hwang I, Maydonovitch C. Nocturnal reflux episodes following the administration of a standardized meal. Does timing matter? Am J Gastroenterol 2007; 102: 2128–34.
36. Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006; 166: 965–71.
37. Stanciu C, Bennett JR. Effects of posture on gastrooesophageal reflux. Digestion 1977; 15: 104–9.
38. Sigterman KE, van Pinxteren B, Bonis PA. Short-term treatment with proton pump inhibitors, H2-receptor antagonists and prokinetics for gastrooesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev 2013; 5: CD002095.
39. Gunaratnam NT, Jessup TP, Inadomi J. Sub-optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastrooesophageal reflux disease. Aliment Pharmacol Ther 2006; 23: 1473–7.
40. Johnson DA, Lauritsen K, Junghard O, Levine D. Evaluation of symptoms is an unreliable predictor of relapse of erosive esophagitis in patients receiving maintenance PPI therapy. Gastroenterology 2003; 124 (4; Suppl. 1): A540.
41. Chey WD, Inadomi JM, Booher AM et al. Primary-care physicians’ perceptions and practices on the management of GERD: results of a national survey. Am J Gastroenterol 2005; 100 (6): 1237–42.
42. Boltin D, Zvidi I, Raskin M et al. Effect of Postprandial Administration of Esomeprazole on Reflux Symptoms in Gastroesophageal Reflux Disease: A Randomized, Controlled Trial. Dig Dis 2018.
43. Talley NJ, Lauritsen K, Tunturi-Hihnala H et al. Esomeprazole 20 mg maintain symptom control in endoscopy-negative gastro-esophageal reflux disease: a controlled trial of ‘on-demand’ therapy for 6 months. Aliment Pharmacol Ther 2001; 15: 347–54.
44. Bayerdörffer E, Bigard Marc-Andre, Weiss W et al. Randomized, multicenter study: on-demand versus continuous maintenance treatment with esomeprazole in patients with non-erosive gastroesophageal reflux disease. BMC Gastroenterology 2016; 16: 48.
45. Lind T, Rydberg L, Kylebaeck A et al. Esomeprazole provides improved acid control vs. omeprazole in patients with symptoms of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2000; 14: 861–7.
46. Andersson Т, Rohss K, Hassan-Alin M, Bredberg E. Pharmacokinetics and dose-response relationship of esomeprasole. Gastroenterology 2000; 118: A1210.
47. Castell D, Castell D, Kahrilas P et al. Esomeprazole provides more effective healing than lansoprazole in GERD patients with erosive oesophagitis. Gut 2001; 49 (Suppl. U): A3363.
48. Kahrilas P, Falk J, Johnson D et al. Esomeprazole improves healing and symptom reso-lution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. Aliment Pharmacol Ther 2000; 14: 1249–58.
49. Richter J, Kahrilas P, Johanson J. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive oesophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96: 656–65.
50. Rohss K, Wilder-Smith C, Claar-Nilsson С et al. Esomeprazole 40 mg provides more effective acid control than standard doses of all other proton pump inhibitors. Gastroenterology 2001; 120: A2140.
51. Wilder-Smith C, Rohss K, Lundin C, Rydholm H. Esomeprazole 40 mg provides more effective acid control than pantoprazole 40 mg. Gastroenterology 2000; 118: A22.
52. Edwards S, Lind Т, Lundell L. Systematic review of proton pump inhibitors for the acute treatment of reflux eosophagitis. Aliment Pharmacol Ther 2001; 15: 1729–36.
53. Li Mei-Juan, Li Qing, Sun Min, Liu Li-Qin. Comparative effectiveness and acceptability of the FDA-licensed proton pump inhibitors for erosive esophagitis. A PRISMA-compliant network meta-analysis. Medicine 2017; 96: 39.
54. Evsiutina Iu.V., Trukhmanov A.S. Novyi vzgliad na problemu gastroezofageal'noi refliuksnoi bolezni, refrakternoi k lecheniiu ingibitorami protonnoi pompy. Ros. zhurn. gastroenterologii, gepatologii, koloproktologii. 2014; 5: 4–9 (in Russian).
55. Maev I.V., Samsonov A.A., Andreev D.N. Rol' i mesto antatsidov v sovremennykh algoritmakh terapii kislotozavisimykh zabolevanii. Farmateka. 2013; 2: 66–72 (in Russian).
56. Wilder-Smith C, Rohss K, Lundin C, Rydholm H. Esomeprazole 40 mg provides more effective acid control than pantoprazole 40 mg. Gastroenterology 2000; 118: A22.
57. Ivashkin V.T., Maev I.V., Trukhmanov A.S. et al. Pishchevod Barreta. Klinicheskie rekomendatsii. Rossiiskaia gastroenterologicheskaia assotsiatsiia. Moscow, 2014 (in Russian).
58. Galmiche JP, Hatlebakk J, Attwood S et al. Laparoscopic antireflux surgery vs esomeprazole treatment for chronic GERD: the LOTUS randomized clinical trial. JAMA 2011; 305: 1969–77.
Авторы
А. С.Трухманов*, Д.Е.Румянцева
ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
ФГАОУ ВО «Первый Московский государственный медицинский университет имени И.М. Сеченова» Минздрава России (Сеченовский Университет), Москва, Россия
________________________________________________
I.M.Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia
Цель портала OmniDoctor – предоставление профессиональной информации врачам, провизорам и фармацевтам.